UVA research sheds light on how cancer remodels our chromosomes

Cancer remodels the architecture of our chromosomes so the disease can take hold and spread, researchers at the University of Virginia have revealed.

UVA research sheds light on how cancer remodels our chromosomes
Chongzhi Zang, PhD, has shed light on how cancer remodels our chromosomes for its own purposes.

This remodeling is important because the arrangement of the components in our chromosomes actually affects the workings of our genes. With these renovations, cancer begins making a comfortable home for itself inside our cells.

Even when the genetic code in DNA sequence may largely remain the same, the three-dimensional structure of chromosomes in cancer can be very different from our normal cells. A better understanding of the cancer genome structure can give us insights for developing new drugs to specifically target the Achilles' heel of each cancer."

Chongzhi Zang, Ph.D., Researcher, Computational Biologist with UVA's Center for Public Health Genomics

Understanding cancer

To make its desired changes inside our chromosomes, cancer relies on a protein called "CCCTC-binding factor," or CTCF for short. CTCF occurs naturally in our cells. In healthy cells, it plays an important role in maintaining the chromosome structure and turning genes on and off as needed. But cancer, Zang found, highjacks CTCF for its own purposes. CTCF appears where it shouldn't, and it doesn't bind where it should. This alters the three-dimensional organization of our chromosomes and changes the way genes work.

To understand CTCF's role in cancer, Zang and his team dived deep into genomic data collected from human tissues and cancer samples. They identified patterns of CTCF remodeling in six different cancers, including T-cell acute lymphoblastic leukemia, acute myeloid leukemia, breast cancer, colorectal cancer, lung cancer, and prostate cancer.

We developed an innovative data science approach to collect and integrate thousands of publicly available datasets to make these findings. It's exciting to see how many new scientific discoveries can be made solely by analyzing the big data that's already out there."

Chongzhi Zang, Ph.D.

The researchers validated their findings by looking specifically at T-cell acute lymphoblastic leukemia, but they say further research into changes into CTCF binding will help scientists better understand the origins of other cancers as well. (Faulty CTCF binding also has been linked with developmental disorders and other conditions, so understanding it may also offer important insights into those diseases as well.)

"The abnormal patterns of CTCF binding that we found is probably a signature existing in every cancer type," Zang said. "These findings brought us one small step closer to fully unraveling the molecular mechanism of cancer, an extremely complex disease."

Findings published

The researchers have published their findings in the scientific journal Genome Biology. The UVA research team consisted of Zhenjia Wang, Aakrosh Ratan, and Zang. The experimental work was done in collaboration with scientists at Northwestern University, University of Miami and Mayo Clinic.

Zang is a member of the School of Medicine's Department of Public Health Sciences and Department of Biochemistry and Molecular Genetics. He is also part of the UVA Cancer Center and UVA's Department of Biomedical Engineering, a collaboration of the School of Medicine and the School of Engineering.

The research at UVA was supported by National Institutes of Health (NIH) grants K22CA204439 and R35GM133712, as well as a Phi Beta Psi Sorority research grant.

Source:
Journal reference:

Fang, C., et al. (2020) Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biology. doi.org/10.1186/s13059-020-02152-7.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Signaling pathway promotes cancer growth by blocking pro-growth signals from second major cancer pathway